A Randomized Controlled Clinical Trial of the Serotonin Type 3 Receptor Antagonist Alosetron in Women With Diarrhea-Predominant Irritable Bowel Syndrome | Zendy

Michael Camilleri | Zendy; William Y. Chey | Zendy; Emeran A. Mayer | Zendy; Allison R. Northcutt | Zendy; Amy Heath | Zendy; George E. Dukes | Zendy; David McSorley | Zendy; Allen W. Mangel | Zendy

Open Access

A Randomized Controlled Clinical Trial of the Serotonin Type 3 Receptor Antagonist Alosetron in Women With Diarrhea-Predominant Irritable Bowel Syndrome

Author(s) -

Michael Camilleri,

William Y. Chey,

Emeran A. Mayer,

Allison R. Northcutt,

Amy Heath,

George E. Dukes,

David McSorley,

Allen W. Mangel

Publication year - 2001

Publication title -

archives of internal medicine

Language(s) - English

Resource type - Journals

eISSN - 1538-3679

pISSN - 0003-9926

DOI - 10.1001/archinte.161.14.1733

Subject(s) - medicine , irritable bowel syndrome , bloating , placebo , constipation , gastroenterology , abdominal pain , diarrhea , tolerability , clinical endpoint , defecation , randomized controlled trial , adverse effect , alternative medicine , pathology

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder seen in primary care practice. The symptoms of IBS, including abdominal pain, discomfort, and abnormal bowel function, may be modulated by activity of the serotonin type 3 receptor (5-HT(3)). The efficacy and tolerability of the 5-HT(3) receptor antagonist alosetron hydrochloride in nonconstipated female patients with IBS were evaluated in a double-blind, randomized, placebo-controlled trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research